Scientific Publications
Peer-reviewed publications written and co-authored by our biostatistics and clinical data experts, sharing research and practical insights from across the field.
A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE) antibody construct, in patients with refractory solid tumors
Multicentre Phase 1 study of the bispecific EpCAM/CD3 BiTE solitomab in refractory solid tumours.
2024-11-06 Anti-C5a antibody IFX-1 treatment versus best supportive care for patients with severe COVID-19
Trial comparing anti-C5a antibody IFX-1 with best supportive care in patients with severe COVID-19.
2024-11-06 Assessing health-related quality of life in patients with Parkinson's disease in a prospective longitudinal study
Prospective longitudinal assessment of health-related quality of life in Parkinson's disease.
2024-11-06 Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma: final results from a phase I study
Final Phase I results for the BiTE construct blinatumomab in relapsed/refractory non-Hodgkin lymphoma.
2024-11-06 Cabergoline versus levodopa monotherapy: a decision analysis
Decision-analytic comparison of cabergoline versus levodopa monotherapy in Parkinson's disease.
2024-11-06 Cost of illness and its predictors for Parkinson's disease in Germany
Cost-of-illness study and predictors for Parkinson's disease in Germany.
2024-11-06 Cost of illness in Parkinson disease. A retrospective 3-month analysis of direct costs
Retrospective 3-month cost-of-illness analysis of direct costs in Parkinson's disease.
2024-11-06 Costs of drug treatment of neurologic diseases: Parkinson disease, dystonia, epilepsy
Analysis of drug-treatment costs across Parkinson disease, dystonia and epilepsy.
2024-11-06 Costs of treating dystonias and hemifacial spasm with botulinum toxin A
Cost analysis of treating dystonias and hemifacial spasm with botulinum toxin A.
2024-11-06 Economic evaluation of maintenance treatment with tacrolimus 0.1% ointment in adults with moderate to severe atopic dermatitis
Economic evaluation of maintenance tacrolimus 0.1% ointment in adults with moderate-to-severe atopic dermatitis.
2024-11-06 Expression of epithelial cellular adhesion molecule (Ep-CAM) in chronic (necro-)inflammatory liver diseases and hepatocellular carcinoma
Study of Ep-CAM expression in chronic inflammatory liver disease and hepatocellular carcinoma.
2024-11-06 Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL
Long-term haematologic relapse-free survival follow-up from a Phase 2 study of blinatumomab in B-lineage ALL with MRD.
2024-11-06 Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia
Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated MRD-positive B-precursor ALL patients.
2024-11-06 Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia
Phase 2 study reporting long-term relapse-free survival with blinatumomab in MRD-positive B-lineage ALL.
2024-11-06 Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia
Phase II trial of blinatumomab showing haematologic and molecular remissions in relapsed/refractory B-precursor ALL.
2024-11-06 Principles and recommendations for incorporating estimands into clinical study protocol templates
Practical principles and recommendations for embedding the ICH E9(R1) estimand framework into protocol templates.
2024-11-06 Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study
Prospective, multicentre, placebo-controlled, double-blind RCT of oral magnesium for migraine prophylaxis.
2024-11-06 SAE reporting in EDC trials
Practical perspectives on serious adverse event reporting within EDC-based clinical trials.
2024-11-06 Strong dose response after immunotherapy with PQ Grass using conjunctival provocation testing
Dose-response findings after PQ Grass immunotherapy assessed by conjunctival provocation testing.
2024-11-06 Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival
Blinatumomab in chemotherapy-refractory MRD B-lineage ALL, showing high response rates and prolonged leukaemia-free survival.
2024-11-06 The anti-C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID-19
Pharmacodynamic evidence that vilobelimab efficiently inhibits C5a in patients with severe COVID-19.
2024-11-06 The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis
Estimation of the economic impact of Parkinson's disease from a 3-month prospective analysis.
2024-11-06 Twice-weekly treatment with tacrolimus 0.03% ointment in children with atopic dermatitis: clinical efficacy and economic impact over 12 months
Clinical efficacy and 12-month economic impact of twice-weekly tacrolimus 0.03% ointment in children with atopic dermatitis.
2024-11-06 Vaccinations in recurrent urinary tract infections — an observation study relating to health economy
Observational health-economics study of vaccination in recurrent urinary tract infections.
2024-11-06 Validation of a menstrual pictogram and a daily bleeding diary for assessment of uterine fibroid treatment efficacy in clinical studies
Validation of a menstrual pictogram and daily bleeding diary as efficacy measures in uterine fibroid treatment studies.
2024-11-06 Vilobelimab in combination with tocilizumab or baricitinib dramatically improves mortality in critically ill COVID-19 patients: a subgroup analysis
Subgroup analysis of vilobelimab combined with tocilizumab or baricitinib in critically ill COVID-19 patients.
2024-11-06 Randomized controlled trials define shape of dose response for Pollinex Quattro Birch allergoid immunotherapy
RCTs characterising the dose-response relationship for Pollinex Quattro Birch allergoid immunotherapy.
2024-10-27 Vilobelimab in combination with tocilizumab may synergistically improve mortality in critically ill COVID-19 patients: a post-hoc analysis of the Phase III PANAMO study
Post-hoc analysis of the Phase III PANAMO study examining vilobelimab combined with tocilizumab in critically ill COVID-19 patients.
2024-10-27 Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
The pivotal multicentre, double-blind, randomised, placebo-controlled Phase 3 PANAMO trial of vilobelimab in mechanically ventilated COVID-19 patients.
2024-10-26No items match the current filters.